Wacker Chemie AG ended 2021 with new all-time highs for sales, earnings and net cash flow.
WACKER is offering its platform for developing and manufacturing plasmid DNA (pDNA) under the brand name PLASMITEC®.
During an online Capital Market Day, Wacker Chemie AG today presented its new sustainable development goals to investors and analysts. WACKER’s new goals are much more ambitious than its previous ones.
Due to the ongoing corona pandemic, Wacker Chemie AG has decided to hold next year’s Annual Shareholders’ Meeting scheduled for May 20, 2022, as a virtual event without the physical presence of its shareholders or their proxies.
Wacker Chemie AG ended Q3 2021 with strong growth in sales and earnings thanks to continued high customer demand across all business divisions.